6549.TWO TaiwanJ Pharmaceuticals Co., Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
6.04 TWD
Close of Nov 6, 2026
5.37 9.80
Market cap
TWD 484M
P/E
-
P/B
7.45x
ROE
-34.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6549.TWO undervalued?

Graham number

The Graham number of TaiwanJ Pharmaceuticals Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TaiwanJ Pharmaceuticals Co., Ltd. fundamental analysis

No fundamental analysis for TaiwanJ Pharmaceuticals Co., Ltd. yet.

TaiwanJ Pharmaceuticals Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatt…

Full company profile